PMID- 37417704
OWN - NLM
STAT- MEDLINE
DCOM- 20231220
LR  - 20231220
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 22
IP  - 12
DP  - 2023 Jul-Dec
TI  - Proton pump inhibitors use prior to COVID-19 hospitalization is associated with 
      higher Clostridioides difficile infection rate.
PG  - 1265-1270
LID - 10.1080/14740338.2023.2234821 [doi]
AB  - BACKGROUND: There are uncertainties regarding associations of prior proton pump 
      inhibitor (PPI) use with susceptibility for COVID-19 and risks associated with 
      SARS-CoV-2 infection. We aimed to evaluate the associations of prior PPI use with 
      outcomes in hospitalized patients with COVID-19. RESEARCH DESIGN AND METHODS: We 
      have retrospectively evaluated a total of 5959 consecutively hospitalized 
      patients with COVID-19 from a tertiary-level institution in the period 
      3/2020-6/2021. Associations of prior PPI use with outcomes of in-hospital 
      mortality, mechanical ventilation, intensive care unit stay, venous 
      thromboembolism, arterial thrombosis, major bleeding, bacteremia, and 
      Clostridioides difficile infection (C. diff.) were evaluated in entire and 
      case-matched cohorts. RESULTS: Among 5959 evaluated patients, there were 1967 
      (33%) PPI users. In an entire cohort, prior PPI use was associated with higher 
      in-hospital mortality and higher occurrence of C. diff. Association of prior PPI 
      use with mortality diminished, whereas association with C. diff. persisted after 
      multivariable adjustments. In a matched cohort, prior PPI use was associated only 
      with higher risk of C. diff. but not other outcomes in line with multivariable 
      analysis. CONCLUSIONS: Although prior PPI use might not have a significant impact 
      on clinical course and mortality of SARS-CoV-2 infection, it may predispose 
      patients to the development of complications like higher occurrence of C. diff. 
      and thus substantially impact the course of treatment.
FAU - Lucijanic, Marko
AU  - Lucijanic M
AUID- ORCID: 0000-0002-1372-2040
AD  - Hematology Department, University Hospital Dubrava, Zagreb, Croatia.
AD  - School of Medicine, University of Zagreb, Zagreb, Croatia.
FAU - Busic, Nikolina
AU  - Busic N
AD  - Department of Internal Medicine, University Hospital Dubrava, Zagreb, Croatia.
FAU - Stojic, Josip
AU  - Stojic J
AD  - Department of Gastroenterology, Hepatology and Clinical Nutrition, University 
      Hospital Dubrava, Zagreb, Croatia.
FAU - Barisic-Jaman, Mislav
AU  - Barisic-Jaman M
AD  - Department of Gastroenterology, Hepatology and Clinical Nutrition, University 
      Hospital Dubrava, Zagreb, Croatia.
FAU - Zagorec, Nikola
AU  - Zagorec N
AD  - Nephrology Department, University Hospital Dubrava, Zagreb, Croatia.
FAU - Lazibat, Karla
AU  - Lazibat K
AD  - School of Medicine, University of Zagreb, Zagreb, Croatia.
FAU - Pasaric, Antica
AU  - Pasaric A
AD  - Clinical Immunology, Allergology and Rheumatology Department, University Hospital 
      Dubrava, Zagreb, Croatia.
FAU - Vrkljan Vuk, Anamarija
AU  - Vrkljan Vuk A
AD  - Hematology Department, University Hospital Dubrava, Zagreb, Croatia.
FAU - Durlen, Ivan
AU  - Durlen I
AD  - Nephrology Department, University Hospital Dubrava, Zagreb, Croatia.
FAU - Mitrovic, Josko
AU  - Mitrovic J
AD  - School of Medicine, University of Zagreb, Zagreb, Croatia.
AD  - Department of Internal Medicine, University Hospital Dubrava, Zagreb, Croatia.
AD  - Clinical Immunology, Allergology and Rheumatology Department, University Hospital 
      Dubrava, Zagreb, Croatia.
FAU - Luksic, Ivica
AU  - Luksic I
AD  - School of Medicine, University of Zagreb, Zagreb, Croatia.
AD  - Maxillofacial Surgery Department, University Hospital Dubrava, Zagreb, Croatia.
FAU - Barsic, Bruno
AU  - Barsic B
AD  - School of Medicine, University of Zagreb, Zagreb, Croatia.
LA  - eng
PT  - Journal Article
DEP - 20230710
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Humans
MH  - Proton Pump Inhibitors/adverse effects
MH  - *COVID-19
MH  - Retrospective Studies
MH  - *Clostridioides difficile
MH  - SARS-CoV-2
MH  - *Clostridium Infections/epidemiology/chemically induced/drug therapy
MH  - Hospitalization
OTO - NOTNLM
OT  - SARS-CoV-2
OT  - complications
OT  - diarrhea
OT  - pantoprazole
OT  - prognosis
EDAT- 2023/07/07 13:05
MHDA- 2023/12/20 06:43
CRDT- 2023/07/07 08:33
PHST- 2023/12/20 06:43 [medline]
PHST- 2023/07/07 13:05 [pubmed]
PHST- 2023/07/07 08:33 [entrez]
AID - 10.1080/14740338.2023.2234821 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2023 Jul-Dec;22(12):1265-1270. doi: 
      10.1080/14740338.2023.2234821. Epub 2023 Jul 10.